Skip to main content
Premium Trial:

Request an Annual Quote

Galileo and First Genetic Trust Collaborate for Pharmacogenomics Services

NEW YORK, June 10 - First Genetic Trust, of Chicago, and Galileo Genomics are collaborating to provide pharmacogenomics services to pharma and biotech, the companies said today.


"The US FDA is on the threshold of creating a regulatory framework to   allow pharmacogenomics to better treat individuals through improved drug development. The combined assets of First Genetic Trust and Galileo will allow us to assist the pharmaceutical industry to develop safer and more effective drugs," said Dr. John Hooper, CEO of Galileo Genomics, said in a statement.


In the collaboration, Galileo, of Montreal, will provide data from patients in the Quebecfounder population and others, as well as its high-throughput genotyping, bioinformatics, and statistical analysis capabilities.

First Genetic Trust will contribute its enTrust genetic banking platform, as well as the channels it has established for recruiting patients in the US for large-scale studies to validate discoveries made in the founder populations. The company, based in Chicagowill also include its computational genomics capabilities, including its genetic pattern discovery and data mining tools.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.